- Citations, last 5 years
- 79
- Works, last 5 years
- 9
- h-index
- 24
- Scientists listed
- 0
- Grants since 2016
- 25
Grants received
2020–2022 · research · R44
A Once-Weekly Oral Tacrolimus-Prednisone Fixed-Dose Combination Therapy for Post-Transplant Maintenance Immunosuppressive Therapy
Stephen Zale · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Development of a LystaMab coated pericardial adhesion barrier
Cameron Austin Best · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2020–2024 · research · Global Health
Lyndra Therapeutics, Inc. - to develop a single administration, extended release (14 days) capsule to deliver ivermectin as a malaria endectocide
Lyndra Therapeutics (United States) · funded by Bill and Melinda Gates Foundation
2019–2021 · cooperative agreement · UG3
A once-weekly oral methadone for maintenance therapy for opioid use disorder
Richard Scranton · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2019–2021 · research · R41
LystaMab Immunotherapy to Inhibit Pericardial Adhesions
Christopher Kane Breuer · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2019–2025 · cooperative agreement · UH3
A once-weekly oral methadone for maintenance therapy for opioid use disorder
Patrick Boen · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · research · R41
Targeted LystaMab Therapy to Optimize Tissue Engineered Vascular Graft Performance
Christopher Kane Breuer · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · cooperative agreement · UG3
An ultra-long-acting oral treatment for opioid use disorder
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2018–2020 · cooperative agreement · UG3
An ultra-long-acting oral treatment for opioid use disorder
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2018–2023 · cooperative agreement · UG3
An ultra-long-acting oral treatment for opioid use disorder
Patrick Boen · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2018–2025 · grant · Gender Equality
Lyndra Therapeutics, Inc. - to develop a single oral administration with extended release for at least 18 days of both levonorgestrel and ethinyl estradiol which effectively a...
Lyndra Therapeutics (United States) · funded by Bill and Melinda Gates Foundation
2017–2022 · research · R01
Development of Ultra Long-Acting Oral HIV Therapies
Stephen Zale · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · Global Health
Lyndra Therapeutics, Inc. - to develop a single administration, extended release (14 days) capsule to deliver ivermectin as a malaria endectocide
Lyndra Therapeutics (United States) · funded by Bill and Melinda Gates Foundation
2017–2019 · research · R44
An Oral Ultra Long-Acting Ivermectin for Malaria Elimination
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Development of Ultra Long-Acting Oral HIV Therapies
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Development of Ultra Long-Acting Oral HIV Therapies
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · research · R44
An Oral Ultra Long-Acting Ivermectin for Malaria Elimination
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Development of Ultra Long-Acting Oral HIV Therapies
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2017–2022 · research · R01
Development of Ultra Long-Acting Oral HIV Therapies
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2017–2018 · research · R43
Novel 3D Printed Architectures for Oral Long-acting Drug Delivery Systems
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis
Maria Palasis · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2016–2017 · contract · N43
IGF::OT::IGF SBIR TOPIC 096:THE DEVELOPMENT LEADING TO THE COMMERCIALIZATION OF A BIORESORBABLE STENTS (BRS) FOR THE TREATMENT OF COARCTATION OF THE AORTA IN NEONATES CAN# 16-8470256
Maria Palasis · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis
Maria Palasis · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Novel Bioabsorbable, Flexible Polymeric Stent for Pulmonary Artery Stenosis
Maria Palasis · Lyndra Therapeutics (United States) · funded by National Institutes of Health
2016–2017 · research · R43
An Oral Long-Acting Doxycycline for Onchocerciasis Eradication: Process Improvement for Small Batch Manufacturing
Andrew Martin Bellinger · Lyndra Therapeutics (United States) · funded by National Institutes of Health